NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Sat, 01/13/2018 - 21:03

Yes, the R21 is eligible … no, you do not need to prepare a justification for the NIH. The link to exercise your extension (notifying your IC) will appear in eRA Commons 90 days before the project end date. You will need to tell your institution that you want to extend your award period one year, and your authorized signing official sends the electronic notification. Your university/institution will let you know what information they need prior to submitting the notification.

Categories: NIH-Funding

By: J

WriteEdit-Grant Questions Blog - Fri, 01/12/2018 - 18:49

Thank you very much

Categories: NIH-Funding

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (UT2 -Clinical Trial Optional)

NIH Funding Announcements - Fri, 01/12/2018 - 13:38
Funding Opportunity PAR-18-580 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA. An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required.
Categories: NIH-Funding

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (U44 - Clinical Trial Optional)

NIH Funding Announcements - Fri, 01/12/2018 - 13:38
Funding Opportunity PAR-18-578 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA. An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required.
Categories: NIH-Funding

By: NCE

WriteEdit-Grant Questions Blog - Fri, 01/12/2018 - 12:52

Dear Writedit,

I have a naive question on no-cost extension. Is R21 eligible for NCE? For the first request, do I need to prepare any justification for the request? Or it is automatically approved upon submitting the request on eRA Commons by the SO?

Thanks!

Categories: NIH-Funding

Notice of Expiration of PAR-16-447 " NIAMS Clinical Trial Implementation Cooperative Agreement (U01)

NIH Funding Announcements - Fri, 01/12/2018 - 12:37
Notice NOT-AR-18-014 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

African Association for Health Professions Education and Research (R25)(Clinical Trials Not Allowed)

NIH Funding Announcements - Fri, 01/12/2018 - 12:29
Funding Opportunity RFA-TW-18-001 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this Fogarty International Center R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs by supporting the establishment of an African Association for Health Professions Education and Research (the "Association"). The Association will serve as a leadership and convening organization to network institutions across sub-Saharan Africa in order to jointly develop, disseminate, and share best practices, innovations, curricula, and policy and to engage in joint activities that will increase the quantity, quality and retention of African health professionals to address the crisis in HIV/AIDS and its' comorbidities on the continent. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on one or more of the following: Courses for Skills Development, Research Experiences, Mentoring Activities, Curriculum or Methods Development, and Outreach to broad communities and multiple stakeholders.
Categories: NIH-Funding

Pediatric Device Consortia Grants Program (P50)

NIH Funding Announcements - Fri, 01/12/2018 - 12:08
Funding Opportunity RFA-FD-18-004 from the NIH Guide for Grants and Contracts. The intended goal of this FOA is to facilitate the development, production, and distribution of pediatric medical devices. Although the FOA is issued by the FDA's Office of Orphan Products Development, the grant application is intended to encompass devices for all pediatric diseases and conditions, not just those that are rare. Applicants will request funding to serve as a nonprofit consortium to provide expert advising and support services to innovators of pediatric medical devices. The advising and services will focus on the total product life cycle for medical devices from concept, through pre-market development, to commercialization, and replacement by subsequent generation of devices. In addition, consortia should also provide expertise on evidence generation, including use of real world evidence, for pediatric device development. The pediatric population (i.e., neonates, infants, children, and adolescents) for medical devices is defined as individuals who are younger than 22 years of age (that is, from birth through the twenty-first year of life not including the twenty-second birthday) at the time of diagnosis or treatment.
Categories: NIH-Funding

Notice of Clarification of Applications Relevant to PAR-17-046 "Exploratory Research for Technology Development (R21)"

NIH Funding Announcements - Fri, 01/12/2018 - 12:08
Notice NOT-GM-18-014 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Expiration of PAR-17-145 "NINDS Postdoctoral Mentored Career Development Award (K01)"

NIH Funding Announcements - Fri, 01/12/2018 - 11:59
Notice NOT-NS-18-034 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Expiration of PAR-16-269 "NIAID Clinical Trial Implementation Grant (R01)"

NIH Funding Announcements - Fri, 01/12/2018 - 11:48
Notice NOT-AI-18-009 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding